Table 3.
Findings from Linear Mixed Models for Suicidal Ideation and Secondary Outcome Variables Among All Participants and Stratified for Gender Identity
| Control group (n = 241) |
Intervention group (n = 242) |
|||||
|---|---|---|---|---|---|---|
| Mean score (95% CI) | MC (95% CI)a from baseline | Mean score (95% CI) | MC (95% CI)a from baseline | MD (95% CI)b | Cohen's d | |
| Suicidal ideation total score | ||||||
| After exposure (T2) | ||||||
| Cisgender male | 2.63 (2.40 to 2.87) | 0.02 (−0.08 to 0.12) | 2.60 (2.39 to 2.82) | −0.04 (−0.13 to 0.05) | −0.03 (−0.35 to 0.29) | −0.01 |
| Cisgender female | 2.57 (2.41 to 2.73) | −0.01 (−0.07 to 0.06) | 2.64 (2.48 to 2.81) | 0.04 (−0.03 to 0.11) | 0.07 (−0.16 to 0.30) | 0.03 |
| Nonbinary/transgender | 3.22 (2.96 to 3.47) | −0.004 (−0.11 to 0.10) | 2.79 (2.53 to 3.05) | −0.06 (−0.16 to 0.05) | −0.42 (−0.79 to −0.06)* | −0.10 |
| All groups combined | 2.81 (2.68 to 2.93) | 0.002 (−0.05 to 0.06) | 2.68 (2.55 to 2.80) | −0.02 (−0.07 to 0.03) | −0.13 (−0.31 to 0.05) | −0.06 |
| 4 weeks later (T3) | ||||||
| Cisgender male | 2.82 (2.58 to 3.06) | 0.21 (0.02 to 0.39)* | 2.58 (2.36 to 2.80) | −0.06 (−0.23 to 0.11) | −0.24 (−0.56 to 0.09) | −0.07 |
| Cisgender female | 2.60 (2.44 to 2.75) | 0.02 (−0.10 to 0.13) | 2.77 (2.60 to 2.93) | 0.16 (0.04 to 0.29)* | 0.17 (−0.06 to 0.40) | 0.07 |
| Nonbinary/transgender | 3.08 (2.82 to 3.33) | −0.14 (−0.34 to 0.05) | 2.89 (2.64 to 3.15) | 0.05 (−0.15 to 0.23) | −0.18 (−0.55 to 0.18) | −0.05 |
| All groups combined | 2.83 (2.70 to 2.96) | 0.03 (−0.07 to 0.12) | 2.75 (2.62 to 2.87) | 0.05 (−0.05 to 0.14) | −0.08 (−0.26 to 0.10) | −0.04 |
| Suicidal ideation future optimism | ||||||
| After exposure (T2) | ||||||
| Cisgender male | 2.53 (2.23 to 2.83) | −0.01 (−0.18 to 0.16) | 2.38 (2.10 to 2.66) | 0.02 (−0.14 to 0.18) | −0.15 (−0.56 to 0.26) | −0.03 |
| Cisgender female | 2.54 (2.34 to 2.74) | −0.01 (−0.13 to 0.10) | 2.50 (2.29 to 2.71) | 0.00 (−0.12 to 0.12) | −0.04 (−0.33 to 0.25) | −0.01 |
| Nonbinary/transgender | 3.10 (2.77 to 3.43) | 0.01 (−0.18 to 0.20) | 2.56 (2.23 to 2.89) | −0.20 (−0.39 to −0.02)* | −0.54 (−1.01 to −0.08)* | −0.10 |
| All groups combined | 2.72 (2.56 to 2.89) | −0.004 (−0.10 to 0.09) | 2.48 (2.32 to 2.64) | −0.06 (−0.15 to 0.03) | −0.24 (−0.47 to −0.01)* | −0.09 |
| 4 weeks later (T3) | ||||||
| Cisgender male | 2.60 (2.28 to 2.92) | 0.06 (−0.23 to 0.35) | 2.24 (1.94 to 2.53) | −0.12 (−0.39 to 0.14) | −0.36 (−0.79 to 0.08) | −0.07 |
| Cisgender female | 2.52 (2.31 to 2.72) | −0.03 (−0.21 to 0.15) | 2.59 (2.37 to 2.81) | 0.09 (−0.10 to 0.28) | 0.07 (−0.23 to 0.38) | 0.02 |
| Nonbinary/transgender | 2.86 (2.53 to 3.20) | −0.23 (−0.53 to 0.06) | 2.78 (2.44 to 3.11) | 0.01 (−0.28 to 0.30) | −0.09 (−0.57 to 0.39) | −0.02 |
| All groups combined | 2.66 (2.49 to 2.83) | −0.07 (−0.22 to 0.08) | 2.54 (2.37 to 2.70) | −0.01 (−0.15 to 0.14) | −0.12 (−0.36 to 0.11) | −0.05 |
| Hopelessness | ||||||
| After exposure (T2) | ||||||
| Cisgender male | 2.66 (2.44 to 2.89) | −0.06 (−0.18 to 0.06) | 2.62 (2.41 to 2.82) | 0.08 (−0.03 to 0.20) | −0.05 (−0.35 to 0.25) | −0.01 |
| Cisgender female | 2.77 (2.62 to 2.92) | −0.12 (−0.20 to −0.04)* | 2.80 (2.64 to 2.95) | −0.13 (−0.22 to −0.05)* | 0.03 (−0.19 to 0.24) | 0.01 |
| Nonbinary/transgender | 3.19 (2.95 to 3.44) | −0.08 (−0.21 to 0.06) | 2.95 (2.71 to 3.19) | −0.22 (−0.36 to −0.09)** | −0.24 (−0.58 to 0.10) | −0.06 |
| All groups combined | 2.88 (2.76 to 3.00) | −0.09 (−0.15 to −0.02)* | 2.79 (2.67 to 2.91) | −0.09 (−0.16 to −0.03)* | −0.09 (−0.26 to 0.08) | −0.05 |
| 4 weeks later (T3) | ||||||
| Cisgender male | 2.76 (2.54 to 2.98) | 0.03 (−0.15 to 0.21) | 2.46 (2.26 to 2.67) | −0.07 (−0.24 to 0.09) | −0.29 (−0.59 to 0.01) | −0.09 |
| Cisgender female | 2.78 (2.64 to 2.93) | −0.11 (−0.22 to 0.01) | 2.92 (2.77 to 3.08) | −0.01 (−0.13 to 0.12) | 0.14 (−0.07 to 0.35) | 0.06 |
| Nonbinary/transgender | 3.13 (2.90 to 3.37) | −0.14 (−0.32 to 0.05) | 2.94 (2.70 to 3.17) | −0.24 (−0.42 to −0.06)* | −0.20 (−0.53 to 0.14) | −0.05 |
| All groups combined | 2.89 (2.77 to 3.01) | −0.07 (−0.16 to 0.02) | 2.77 (2.66 to 2.89) | −0.11 (−0.20 to −0.01)* | −0.12 (−0.28 to 0.05) | −0.06 |
| Mood | ||||||
| After exposure (T2) | ||||||
| Cisgender male | 2.81 (2.64 to 2.99) | −0.01 (−0.10 to 0.09) | 2.93 (2.77 to 3.09) | 0.10 (0.01 to 0.19)* | 0.12 (−0.12 to 0.35) | 0.04 |
| Cisgender female | 2.86 (2.74 to 2.98) | 0.05 (−0.01 to 0.12) | 2.74 (2.62 to 2.87) | 0.04 (−0.03 to 0.10) | −0.12 (−0.28 to 0.05) | −0.06 |
| Nonbinary/transgender | 2.61 (2.42 to 2.80) | 0.01 (−0.10 to 0.11) | 2.76 (2.58 to 2.95) | 0.13 (0.03 to 0.23)* | 0.16 (−0.11 to 0.43) | 0.05 |
| All groups combined | 2.76 (2.67 to 2.85) | 0.02 (−0.04 to 0.07) | 2.81 (2.72 to 2.91) | 0.09 (0.04 to 0.14)** | 0.05 (−0.08 to 0.19) | 0.04 |
| 4 weeks later (T3) | ||||||
| Cisgender male | 2.84 (2.63 to 3.05) | 0.01 (−0.22 to 0.24) | 3.07 (2.88 to 3.26) | 0.24 (0.03 to 0.45)* | 0.24 (−0.05 to 0.52) | 0.07 |
| Cisgender female | 2.98 (2.84 to 3.11) | 0.17 (0.03 to 0.32)* | 2.74 (2.59 to 2.88) | 0.03 (−0.13 to 0.18) | −0.24 (−0.44 to −0.04)* | −0.11 |
| Nonbinary/transgender | 2.81 (2.59 to 3.03) | 0.20 (−0.03 to 0.44) | 2.90 (2.68 to 3.11) | 0.26 (0.03 to 0.49)* | 0.09 (−0.22 to 0.40) | 0.03 |
| All groups combined | 2.87 (2.76 to 2.98) | 0.13 (0.01 to 0.25)* | 2.90 (2.79 to 3.01) | 0.18 (0.06 to 0.29)* | 0.03 (−0.13 to 0.18) | 0.02 |
*
p < 0.05; **p < 0.01 (two-tailed).
a
Comparison of means with baseline with Bonferroni-corrected contrast tests.
b
Comparison of means for intervention group with the control group with Bonferroni-corrected contrast tests.
CI, confidence interval; MC, mean change; MD, mean difference.